Date: 2015-09-24
Type of information: Nomination
Compound:
Company: PlaqueTec (UK)
Therapeutic area: Cardiovascular diseases - Diagnostic
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 24, 2015, PlaqueTec, the Cambridge-based company pioneering the development a biomarker-based approach to transform the understanding of coronary artery disease (CAD), announced the appointment of Dr Tim Brears as chief executive.Dr Brears has many years’ experience in the biopharmaceutical industry and was, until recently, Chief Executive of Xention, a company he founded in 2002 and which has become a leader in the development of drugs for the control of atrial fibrillation. Prior to forming Xention, he was Chief Executive of Gendaq, a gene-regulation company, which was acquired by Sangamo Biosciences in 2001. From 1993 to 1999 he was director of licensing at Ciba-Geigy (later Novartis) Agribusiness in Research Triangle Park, North Carolina. Tim graduated from Oxford University in 1983 and was awarded a PhD from Cambridge University in 1987. He subsequently held an EMBO post-doctoral fellowship at Rockefeller University, New York. He holds an MBA from Duke University’s Fuqua School of Business and is a registered US patent agent.
Financial terms:
Latest news:
